Effects of TNF-Alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis - Full Text View

Sponsor:	Massachusetts General Hospital
Collaborator:	Amgen
Information provided by:	Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00477191

Purpose

People with psoriasis have significantly higher rates of obesity, diabetes, heart failure and high blood pressure than the general public. The purpose of this study is to determine how substances produced in the fat (inflammatory markers) relate to the risk of heart disease in people with the metabolic syndrome and psoriasis. People with metabolic syndrome have insulin resistance, increased waist size, high blood pressure, or high cholesterol.

Condition	Intervention
Psoriasis Metabolic Syndrome Hyperlipidemia Obesity Hypertension	Drug: Etanercept (TNF-alpha antagonist)

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Effects of TNF-Alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Resource links provided by NLM:

Genetics Home Reference related topics: hypercholesterolemia

MedlinePlus related topics: Cholesterol High Blood Pressure Obesity Psoriasis

Drug Information available for: Etanercept Tumor Necrosis Factors

U.S. FDA Resources

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:

Determine the effect of TNF-alpha antagonism with Etanercept on CRP levels from baseline to 6 months of treatment in subjects with psoriasis and metabolic syndrome. [ Time Frame: 6 months ]

Secondary Outcome Measures:

Determine the effect of TNF-alpha antagonism with Etanercept in patients with psoriasis and metabolic syndrome on PASI scores and markers of cardiac risk including inflammatory cytokines, acute phase reactants, lipid parameters and glucose tolerance. [ Time Frame: 6 months ]
Determine the effect of 6 months of TNF-alpha antagonism with Etanercept on endothelial function by measurement of flow-mediated vasodilation. [ Time Frame: 6 months ]
Determine the safety and tolerability of Etanercept in patients with psoriasis and metabolic syndrome over a 6-month period. [ Time Frame: 6 months ]

Estimated Enrollment:	40
Study Start Date:	May 2007

Detailed Description:

People with psoriasis have significantly higher rates of obesity, diabetes, heart failure and high blood pressure than the general public. The purpose of this study is to determine how substances produced in the fat (inflammatory markers) relate to the risk of heart disease in people with the metabolic syndrome and psoriasis. People with metabolic syndrome have insulin resistance, increased waist size, high blood pressure, or high cholesterol. Insulin resistance means that the body does not respond well to the insulin in your blood. Therefore, both blood levels of insulin and glucose (sugar) are high.

This causes inflammation (irritation) in the body. Inflammation can cause an unhealthy response in your body and blood vessels, and can lead to blockages in the heart and other vessels.

TNF-alpha is a substance made by fat and inflammatory cells that helps cause inflammatory reactions. TNF-alpha is thought to be important in causing psoriasis. The drug Etanercept blocks TNF-alpha's actions, and has been approved by the Food and Drug Administration (FDA) for the treatment of psoriasis. We think that Etanercept may also reduce the inflammation associated with metabolic syndrome and decrease the risk of heart disease. People in this study will receive either Etanercept or placebo (contains no active drug).

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

hyperinsulinemia
moderate to severe psoriasis
two of the following: obesity, dyslipidemia (high cholesterol), hypertension (high blood pressure)

Exclusion Criteria:

On insulin or other diabetes (anti-hyperglycemic) medication
Congestive Heart Failure
Heart Attack, Stroke or Transient Ischemic Attack in last 3 months
Unstable angina
Pulmonary disease requiring oxygen
SLE, optic neuritis, transverse myelitis, epilepsy
Positive PPD
Scheduled for upcoming surgery
Known immunosuppression (for example, HIV)
Known autoimmune disease
Hepatitis B or Hepatitis C
Pregnant or nursing
Renal insufficiency (Creatinine >1.5)
Latex allergy
Use of live vaccination in past 90 days
Organ transplantation
History of severe infection
History of malignancy (except cured non-melanoma skin cancer)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00477191

Contacts

Contact: Christina N Alavian, MD

617 726-5066

calavian@partners.org

Locations

United States, Massachusetts
Massachusetts General Hospital	Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: Alexandra B Kimball, MD, MPH
Sub-Investigator: Christina N Alavian, MD
Sub-Investigator: Maria B Alora-Palli, MD
Sub-Investigator: Andreas Boker, MD
Sub-Investigator: Gabriela Rolz-Cruz, MD

Sponsors and Collaborators

Massachusetts General Hospital

Amgen

Investigators

Principal Investigator:

Alexandra B Kimball, MD, MPH

Massachusetts General Hospital, Brigham & Women's Hospital

More Information

Additional Information:

Click here for more information about this study: Effects of TNF-alpha Antagonism in Patients with the Metabolic Syndrome and Psoriasis This link exits the ClinicalTrials.gov site

This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	2007-P-000494
Study First Received:	May 18, 2007
Last Updated:	May 24, 2007
ClinicalTrials.gov Identifier:	NCT00477191 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:

psoriasis
metabolic syndrome
Syndrome X
diabetes
insulin resistance

obesity
hypertension
hyperlipidemia
hypercholesterolemia

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Immunologic Factors
Physiological Effects of Drugs
Overweight
TNFR-Fc fusion protein
Body Weight
Signs and Symptoms
Pathologic Processes
Psoriasis
Sensory System Agents
Therapeutic Uses
Syndrome
Nutrition Disorders
Cardiovascular Diseases
Anti-Inflammatory Agents, Non-Steroidal

Analgesics
Dyslipidemias
Obesity
Metabolic Diseases
Hyperlipidemias
Disease
Skin Diseases
Gastrointestinal Agents
Vascular Diseases
Immunosuppressive Agents
Pharmacologic Actions
Analgesics, Non-Narcotic
Overnutrition
Peripheral Nervous System Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on February 08, 2010